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Summary Two faecal occult blood tests (FOBTs), Hemoccult II (guaiac based) and Hemeselect
(immunochemical) were compared in a population screening for colorectal cancer on 24 282 subjects aged
40-70. Hemeselect was interpreted according to a lower (+ and +) and a higher (+) positivity threshold. A
total of 8008 compliers were enrolled in the study. Positivity rates: Hemoccult=6.0%, Hemeselect (+ and
±) =8.2%, Hemeselect (+) =3.1%. Among FOBT-positive subjects complying with the diagnostic work-up, 22
had colorectal cancer (17 Hemeselect-positive (+), four Hemeselect-borderline (±), 15 Hemoccult-positive) and
166 subjects had adenomas (62 Hemeselect(+), 56 Hemeselect-borderline (±), 79 Hemoccult-positive) were
detected. The positive predictive values (PPVs) for cancer were as follows: Hemoccult=3.7%, Hemeselect (+
and +) =3.8%, Hemeselect (+) =8.4%. The PPVs for adenoma(s) were: Hemoccult = 19.7%, Hemeselect (+
and +) =21.4%, Hemeselect (+) =30.5%. The specificity for cancer was: Hemoccult=94.1%, Hemeselect (+
and +) = 92%, Hemeselect (+) = 97.1%. Ratios between detection rates of each test and expected incidence of
colorectal cancer suggest that Hemoccult anticipates cancer diagnosis by approximately 2 years on average
whereas the mean diagnostic anticipation of Hemeselect ranges between 2.5 and 3.2 years. Hemeselect is
superior to Hemoccult as it is at least as effective but more efficient and acceptable than guaiac testing. Further
evaluation of Hemeselect cost-effectiveness and sensitivity is needed in order to assess the optimal threshold of
positivity and screening frequency.
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In recent years several randomised (Mandel et al., 1993) or
case-control studies (Selby et al., 1993; Wahrenrdorf et al.,
1993; Lazovich et al., 1995) have reported guaiac-based faecal
occult blood testing (Hemoccult II, SmithKline Diagnostics,
San Jose, CA, USA) to reduce mortality from colorectal
cancer (CRC). The Minnesota Colon Cancer Control Study
(Mandel et al., 1993) has demonstrated that annual screening
by rehydrated Hemoccult II is able to achieve a 33%
reduction of mortality from CRC. Thus rehydrated
Hemoccult may be taken to be the standard test for
comparison of any other new faecal occult blood test
(FOBT) in CRC screening. In the above-mentioned study
rehydrated Hemoccult shows a high sensitivity for CRC
(92.2%) but the corresponding specificity value is disappoint-
ingly low (90.4%), causing a high referral rate to colonoscopy
(9.8%) and a relevant increase in screening costs. Another
test, Hemeselect (SmithKline Diagnostics, San Jose, CA,
USA), based on reverse-passive haemagglutination, has been
(found to show) increased sensitivity as compared with
Hemoccult (Castiglione et al., 1992; St John et al., 1993;
Petrelli et al., 1994; Castiglione et al., 1994; Robinson et al.,
1994) and also evidence of effectiveness in reducing mortality
from CRC (Saito et al., 1995). In our preliminary experiment
(Castiglione et al., 1992; 1994) in self-referring subjects Iday
Hemeselect testing showed a higher detection rate for cancer
and adenomas as compared with 3 day rehydrated Hemoccult
whereas specificity did not significantly differ. These results
suggest that 1 day Hemeselect may be more accurate than
rehydrated Hemoccult. Moreover, Hemeselect requires no
dietary restriction, a condition which is likely to increase the
compliance with screening.
The aim of the present study is to compare the accuracy of
1 day Hemeselect and 3 day rehydrated Hemoccult in a
population-based screening programme in the Province of
Florence.
Methods
A population-based screening programme for CRC by
Hemoccult has been in progress since 1982 in 28 munici-
palities in the province of Florence. All subjects aged 40-70
living in the screening area have been invited every other year
to undergo the screening protocol, run by the Centro per lo
Studio e la Prevenzione Oncologica of Florence.
From March 1992, screening was initiated in four newly
involved municipalities (14 682 inhabitants aged 40-70) with
a new protocol based on two FOBTs. Attendance rates
ranged between 38% and 48% (mean=44%). In 1994 the
new protocol was introduced in two municipalities previously
screened by Hemoccult alone (9600 subjects aged 40-70).
Attendance rates in these two municipalities were 37% and
38% (mean=37.5%).
In the present study only the first attendance with the new
protocol was considered for each subject, provided both tests
had been completed. Subjects previously screened by
Hemoccult alone were included in our study provided at
least 3 years had elapsed since the most recent screening.
Attenders were asked to collect faeces samples using
Hemoccult kits on three consecutive bowel movement and
Hemeselect kits on the first bowel movement only. Compliers
were invited not to eat red meat 2 days before and during
faeces samples collection. Returned specimens were developed
in our laboratory usually within 1 week from faeces samples
collection. Hemoccult was developed after rehydration and
was considered positive when a blue colour appeared at least
in one slide after application of one drop of developer.
Hemeselect was interpreted at 1/8 dilution according to two
positivity thresholds: positive (+) or borderline (±). After
erythrocytes coated with anti-human haemoglobin antibodies
were added to the diluted extract of faecal specimens,
Hemeselect reactions were considered negative when no
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agglutination was evident. Reactions were considered as
borderline (±) when erythrocytes formed a ring around a
compact button, slightly greater in diameter than in the
negative control well, with slight peripheral agglutination.
Hemeselect was considered positive (+) when erythrocytes
formed a ring greater in diameter and thinner than that in the
negative control well or appeared filmy and spread out to
uniformly cover the bottom of the well with or without
centripetal sliding.
Subjects who were negative on both Hemoccult and
Hemeselect tests were invited to a repeat screening after 2
years, and to visit their family doctors about any complaint
occurring during that interval. Subjects with a positive
Hemoccult and/or a positive/borderline Hemeselect test were
invited to undergo pancolonoscopy. Double contrast barium
enema was undertaken when pancolonoscopy was not
possible. FOBT-positive subjects who did not complete the
diagnostic work-up within 3 months from the date of testing
were assumed as lost to follow-up for the purposes of the
study.
Positivity rates ofrehydrated Hemoccult or Hemeselect (+
and +) or (+ only) were calculated in the overall series and
according to age.
Corresponding positive predictive values (PPVs) for cancer
and/or adenomas and detection rates for cancer were
calculated after exclusion of those FOBT-positive subjects
who did not complete the diagnostic work-up.
Specificity for cancer was calculated as the proportion of
subjects without cancer who were negative on each test
independently of the performance of any diagnostic work-
up. According to this approach, subjects with both
Hemoccult and Hemeselect-negative tests not undergoing
any diagnostic assessment were assumed to be free of CRC.
This assumption (Morrison, 1985, pp. 142-144) is justified
since the frequency of CRC in the general population,
especially in FOBT-negative subjects, is sufficiently low to
allow a satisfactory estimate of specificity by taking as non-
diseased all subjects not found to have CRC. FOBT-positive
subjects not undergoing any diagnostic work-up were
assumed as negatives as far as specificity for cancer was
concerned.
Differences in positivity rates, PPVs and specificity of
Hemoccult and Hemeselect were checked by the chi-square
test, statistical significance being set at P<0.05.
The ratio between detection rate (prevalence) and expected
incidence of CRC was calculated for each test. The expected
incidence was estimated by means of the age - sex specific
incidence rates of CRC in the Province of Florence (Zanetti
and Crosignani, 1992).
The 95% confidence interval for proportions was
calculated using the normal approximation to the binomial;
when the normal approximation was not valid, the exact
confidence intervals were calculated. The 95% confidence
intervals for the prevalence-incidence (P/I) ratios were
calculated assuming a Poisson distribution for the numera-
tors of the prevalence rates.
The relative sensitivity between tests (Morrison, 1985,
pp. 62-64)) were calculated and then tested by means of the
McNemar test (McNemar, 1947).
Results
From March 1992 to July 1995, 8008 subjects were recruited
to the present study. There were 3784 males, mean age = 54.1
years of whom 2431 were over the age of 49; 4224 were
females, mean age= 54.2 years, of whom 2734 were over 49.
Data on the performance of Hemoccult and Hemeselect
tests in the overall series are reported in Table I. Positivity
rate was highest for Hemeselect (+ and +) and lowest for
Hemeselect (+), differences between tests being statistically
significant (P<0.00001).
Hemeselect (+) had the highest PPV for cancer (P<0.05)
and for adenomas (P<0.01). Significant differences
(P<0.001) of cumulative PPVs for cancer and all size
adenomas were observed between Hemoccult and Hemese-
lect (+) (23.4% vs 38.9%) or Hemeselect (+ and +) and
Hemeselect (+) (25.2% vs 38.9%). The same differences were
evident when the cumulative PPVs for cancer and adenomas
> 9 mm were considered.
Specificity for cancer was highest for Hemeselect(+) and
lowest for Hemeselect (+ and +), differences between tests
being statistically significant (P<0.0001).
The relative sensitivity of Hemoccult vs Hemeselect (+) or
Hemeselect (+ and +) was 88.2% (P<0.05) or 71.4%
(P<0.05) respectively. The relative sensitivity of Hemeselect
(+) vs Hemeselect (+ and +) was 80.9% (P<0.05).
Table II shows the distribution of cancers according to
Dukes' stage and each test result. All of the 12 Dukes' A
carcinomas were detected by Hemeselect (+ and +).
Hemoccult and Hemeselect(+) detected five and eight
Dukes' A cancers respectively.
Table I Positivity rates, diagnostic yields, positive predictive values (PPV) for cancer or adenomas
and specificity for cancer of each test in the overall series (8008 subjects)
Rehydrated Hemeselect Hemeselect
Hemoccult I day I day Total
3 days + and + + only detected
Number of positive tests 483 655 245
Positivity rates 6.0% 8.2% 3.1%
(CI) (5.5-6.5) (7.6-8.8) (2.7-3.4)
Completed work-up (%) 400 (82.8) 551 (84.1) 203 (82.9)
Cancer patients 15 21 17 22
PPV for cancer 3.7% 3.8% 8.4%
(CI) (1.9-5.6) (2.2-5.4) (4.6- 12.2)
Adenoma patients 79 118 62 166
>9mm 37 55 36 70
< lOmm 42 63 26 96
PPV for adenomas 19.7% 21.4% 30.5%
(CI) (15.8-23.6) (18.0-24.8) (24.2-36.9)
>9mm 9.2% 10.0% 17.7%
< lOmm 10.5% 11.4% 12.8%
Specificity for cancer 94.1% 92.0% 97.1%
(CI) (93.6-94.6) (91.4-92.6) (96.7-97.5)
CI, 95% confidence interval.Table III shows positivity rates and diagnostic yield in
FOBT-positive subjects completing the diagnostic work-up.
Also shown are the PPVs for cancer and adenomas, as well as
specificity values according to age. Differences in perfor-
mance between tests in the overall series remained almost
unchanged when determined only in subjects aged 50-70. In
subjects aged 40-49, differences between positivity rates and
specificity estimates for cancer observed in the overall series
were confirmed whereas PPVs for cancer and adenomas did
not reach statistical significance, perhaps because of the very
low prevalence of both cancer and adenomas. When the
performance of each test in subjects younger than 50 or 50
and older were compared, positivity rates and PPVs for
cancer and adenomas of single tests were significantly higher
in the older than in the younger age group. The reverse was
true for specificity for cancer.
Table IV shows the P/I ratio for CRC of each test in the
overall series and according to age.
Discussion
In the present study we have compared the performances of
rehydrated Hemoccult with that of 1 day Hemeselect. In our
Table II Screen-detected cancers according to Dukes' stage and
each test positivity
Rehydrated Hemeselect Hemeselect
Dukes' Hemoccult I day 1 day Total
stage positive + and + + only detected
A 5 12 8 12
B 3 3 3 3
C 1 1 1 1
D 2 2 2 2
Not available 4 3 3 4
Total 15 21 17 22
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series the positivity rate of rehydrated Hemoccult in subjects
aged 50-70 years was lower than reported in the Minnesota
Colon Cancer Control Study (6.9% vs 9.8% respectively)
(Mandel et al., 1993). Other differences between our data and
those in the Minnesota trial concern PPVs for cancer (4.4%
vs 2.2% respectively) and specificity for cancer (93.3% vs
90.4% respectively). These differences may be partially
explained by different age distributions (Mandel et al.,
1994) and possible self-selection biases of enrolled subjects,
different dietary restrictions and reader's interpretation of
results (Castiglione et al., 1994).
In the present study 1-day Hemeselect was interpreted
according to two different thresholds of positivity. When a
lower positivity threshold (+ and +) of Hemeselect is
considered, the positivity rate is significantly higher whereas
specificity is significantly lower compared with Hemoccult.
Nevertheless, such an increase in referral rate for colonoscopy
and of overall screening costs may be acceptable in our
experience, as the PPV for cancer and/or adenomas was
comparable with that of Hemoccult and a larger number of
cancers and adenomas were detected. It is noteworthy that of
the 12 Hemeselect-detected Dukes' A cancers, seven were
Table IV Prevalence/incidence ratios for colorectal cancer of each
test in the overall series and according to age
Rehydrated Hemeselect Hemeselect
Hemoccult 1 day I day
3 days + and + + only
Age 50-69 years 2.2 3.2 2.5
(CI) (1.2-3.8) (1.9-5.0) (1.4-4.2)
Age 40-49 years 2.7 2.7 2.7
(CI) (0.3-9.8) (0.3-9.8) (0.3-9.8)
Overall series 2.3 3.2 2.5
(CI) (1.3-3.7) (1.9-4.8) (1.7-4.4)
CI, 95% confidence interval.
Table III Positivity rates, diagnostic yields, positive predictive values (PPV) for cancer
or adenomas and specificity for cancer of each test according to age
Rehydrated Hemeselect Hemeselect Total
Hemoccult + and + + only detected
SUBJECTS AGED 50-70 (n = 5165)
No. of positive tests 354 (6.8%) 479 (9.3%) 181 (3.5%)
(CI) (6.2-7.5) (8.5-10.1) (3.0-4.0)
Completed work-up (%) 297 (83.9) 401 (83.7) 150 (82.9)
Cancer patients (PPV) 13 (4.4%) 19 (4.7%) 15 (10.0%) 19
(CI) (2.0-6.7) (2.7-6.8) (5.2- 14.8)
Adenoma patients (PPV) 71 (23.9%) 101 (25.2%) 57 (38.0%) 142
(CI) (19.1-28.8) (20.9-29.4) (30.2-45.8)
>9mm (PPV) 35 (11.8%) 49 (12.2%) 33 (22.0%) 62
<lOmm (PPV) 36 (12.1%) 52 (13.0%) 24 (16.0%) 80
Specificity for cancer 93.3% 91.0% 96.7%
(CI) (92.6-94.0) (90.2-91.8) (96.2-97.2)
SUBJECTS AGED 40-49 (n = 2843)
No. of positive tests 129 (4.5%) 175 (6.2%) 64 (2.2%)
(CI) (3.7-5.3) (5.3-7.1) (1.7-2.8)
Completed work-up (%) 103 (79.8) 150 (85.2) 53 (82.8)
Cancer patients (PPV) 2 (1.5%) 2 (1.3%) 2 (3.8%) 3
(CI) (0.1-6.5) (0.1 -5.9) (0.5- 13.0)
Adenoma patients (PPV) 8 (7.8%) 17 (11.3%) 5 (9.4%) 24
(CI) (2.6- 12.9) (6.3- 16.4) (1.6- 17.3)
>9mm (PPV) 2 (1.9%) 6 (4.0%) 3 (5.7%) 8
<1Omm (PPV) 6 (5.8%) 11 (7.3%) 2 (3.8%) 16
Specificity for cancer 95.5% 93.9% 97.8%
(CI) (94.7-96.3) (93.0-94.8) (97.2-98.3)
Cl, 95% confidence interval.S t by facal occult bWood -
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undetected by Hemoccult. This fact suggests that the
increased detection rate of Hemeselect (+ and +) as
compared with Hemoccult particularly concerns earlier
stage-cancers and foretells a higher efficacy of screening in
reducing CRC mortality and incidence.
When a higher positivity threshold was adopted (+).
Hemeselect positivity rate decreased significantly and our
results became consistent with those reported in a case-
control study (Saito et al.. 1995) that demonstrated
Hemeselect effectiveness in reducing mortality from CRC.
Using this positivity criterion, approximately 50% or 40%
reduction of positive results was recorded as compared with
Hemoccult or Hemeselect (+ and +) respectively; improve-
ments in specificity for cancer and in PPV for cancer and
adenomas were also obtained. This costs a reduction by 20%
in screen-detected cancer prevalence as compared with
Hemeselect (+ and +). Nevertheless, Hemeselect (-+t)
detection rate for cancer was still higher as compared with
Hemoccult. A reduction in the frequency of screen-detected
adenomas was also observed when a higher threshold of
positivity was adopted for Hemeselect. although most of the
difference was accounted for by <1 cm adenomas. In fact
Hemeselect (i) detects almost as many > 1 cm adenomas as
Hemoccult.
Our data confirm that screening by Hemeselect is superior
to Hemoccult. In fact Hemeselect is either as effective as
Hemoccult with a significant improvement of specificity or
significantly more sensitive than guaiac testing with a minor
decrease in specificity according to the higher (+ ) or the
lower (+ and +) positivity threshold respectively. Moreover.
an important advantage of Hemeselect is to allow for a
greater acceptability of screening as a single faecal sampling
and no dietary restriction is required.
The prevalence-incidence (P I) ratio is considered to be
an indicator of the mean sojourn time of cancer in the
preclinical detectable phase. Assuming an exponential
distribution. the P I ratio is an estimate of the mean lead
time of a screening test. i.e. the time period by which the
diagnosis of cancer has been anticipated on average (Day et
al.. 1988).
In our data this figure is hardly higher than 2 as far as
Hemoccult is concerned. This fact is consistent with the little,
non-significant reduction in mortality from CRC in the
biennial arm of the Minnesota Colon Cancer Control Study
(Mandel et al., 1993). In our series a longer protective effect
of Hemeselect as compared with Hemoccult is suggested as
the P I ratio of this test in the overall series is 2.5 or 3.2
according to the higher (-+) or the lower (+ and +)
Hemeselect positivity threshold respectively.
Our data confirm a very low occurrence of colonic
neoplasms in average risk subjects under the age of 50.
This makes screening in this age group highly questionable
for cost-effectiveness considerations and has persuaded us to
modify the age limits of the inVited population in our
programme.
The exact impact of Hemeselect testing on screening cost-
effectiveness needs to be carefully evaluated and will be the
subject of a separate report.
Further efforts for the evaluation of Hemeselect sensitivity
for CRC will be necessary in the future in order to assess the
optimal positivity threshold and frequency of Hemeselect
testing.
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